Prior Stephen David 4
4 · AN2 Therapeutics, Inc. · Filed Jan 7, 2025
Insider Transaction Report
Form 4
Prior Stephen David
Chief Strategy Officer
Transactions
- Sale
Common Stock
2025-01-03$1.34/sh−2,029$2,721→ 33,313 total
Footnotes (2)
- [F1]Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2025.
- [F2]Includes (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 and (b) 12,031 RSUs which shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.